Meeting report
Lipid lowering drugs Keywords: lipid lowering drugs; statins: fibrates; nicotinates; marine oils There has been a proliferation in the development of drugs designed to lower blood lipids particularly with the development of the new HMG Co-A reductase inhibitors. The meeting therefore was to discuss the new developments with regard to lipid lowering therapy and its application in the field of preventive medicine.
Professor D J Galton (London) opened the meeting by pointing out that in 1970 there were only three major drugs in clinical use for lipid-loweringand that now there are more than 14 drugs with different mechanisms of action that can be broadly classified as: bile-acid resins; fibrates; statins; antioxidants; nicotinates and marine oils. The pharmaceutical industry is actively searching and developing new and more powerful agents, particularly in view of the prevalence of the hyperlipidaemias in Western populations. The hyperlipidaemias are being underdiagnosed and a survey of various countries showing the percentage of the population who know their own lipid levels is extremely variable; for example 62% of a sample of 17 000 Frenchmen knew their own lipid levels, 52% of a sample of 4000 Belgians knew their levels, whereas only 7% of a sample of 37 000 UK subjects ever had their lipids tested. The neglect of the hyperlipidaemias in the UK may be perhaps due to the over-emphasis of the other risk factors for atherosclerosis, particularly smoking and hypertension in which UK physicians have played a prominent role in identifying aetiological links.
In terms of prescription of lipid lowering drugs to patients amongst different countries, there is also wide variation with approximately 20 000 000 patient days of therapy being employed in the Federal Republic of Germany and less than 1 000 000 patient days in the UK. Similarly if one looks at the prescription of hypolipidaemic drugs in comparison to other drugs commonly used to treat hypertension and diabetes, there is a large difference in prescribing habits. Hypolipidaemic drugs are being prescribed at approximately one fortieth the use of beta-blockers or anti-diabetic drugs. The neglect of the use of hypolipidaemic agents may well account for the high rates of coronary heart disease that are found in the UK.
With regard to the beneficial effects of cholesterol lowering, Dr R Collins (Oxford)gave a survey of all the trials that have taken place, to assess the beneficial effects of lipid lowering. Overall, the epidemiological evidence suggests that a fall of about 10% in plasma cholesterol would correspond to about one-third less coronary heart disease and that a prolonged 30% fall in plasma cholesterol would correspond to about a 4-fold difference in coronary heart disease rates. These are the results of 22 randomized trials of various cholesterol lowering drugs and diets (totalling approximately 42000 subjects) and conclusively demonstrate the value of lipid lowering. There may be a slight increase of noncardiac mortality in those patients treated in these trials but Dr Collins thought this may be largely due to the play of chance since it is spread over several diseases (which would be expected if this were a chance effect and epidemiologically, although established cancer can lower the bloodcholesterol, low cholesterol does not in itself appear to cause cancer or other non-coronary heart disease mortality). He made the final point that in assessing the evidence for cholesterol lowering, it is appropriate to consider the results of a systematic overview of all the relevant randomized trials in the context ofthe epidemiological evidence.
The efficacy and safety of the new HMG Co-A reductase inhibitors were reviewed by Dr J Tohert (USA). HMG-CoA reductase is an important ratelimiting step in the cholesterol biosynthesis pathway, and it has been shown that inhibition of this enzyme leads to a marked reduction of plasma cholesterol. Reduction of the cholesterol level within hepatocyte causes an induction of cell surface LDL receptors, which increases the catabolism ofLDL cholesterol and therefore reduces bloodLDLcholesterolconcentrations. The first such inhibitor to be approved for therapeutic use was lovastatin, which has been available since 1987 in the USA and subsequently in numerous other countries. The second is simvastatin, which was first approved in Sweden in 1988 and subsequently in several other countries including the UK in 1989. A third inhibitor, pravastatin, is available in Japan and recently in Ireland and Italy. At the maximum recommended dosages, simvastatin and lovastatin produce mean reductions in plasma and LDL cholesterol of 33% and 40%, respectively. HDL increases by about 10%. Based on the results of intervention studies with other lipid-lowering agents, it is likely that reductions in LDL cholesterol of this magnitude will produce a substantial reduction in coronary risk, and several studies to test this hypothesis are currently underway.
The tolerability and safety of simvastatin and lovastatin have been established by clinical trials totalling over 20 000 patients, and marketed use in approximately two million patients (1.5 million on lovastatin, 0.5 million on simvastatin), Principal adverse effects are marked by asymptomatic increases in transaminases, which occur in about 1%ofpatients, and myopathy, characterized by muscle pain and/or weakness and markedly elevated creatinine kinase levels, in 0.1% of patients. Physician and patient awareness of the possibility of myopathy is important, because failure to stop therapy promptly can lead to acute renal failure due to myoglobinuria. The risk of myopathy is substantially increased by concomitant therapy with gemfibrozil (and probably other fibrates), niacin, and immunosuppressive therapy including cyclosporine. A recently completed 48-week study of lovastatin in over 8000 patients showed that these Report of meeting of Forum on Lipids, 5 June 1990 0141-0768/90/ 110750-04/$02.00/0 © 1990 The Royal Society of Medicine adverse effects are dose-dependent. The frequency of marked increases in transaminases at 20, 40 and 80 mg/day was 0.1%,0.9% and 1.5% respectively. The corresponding incidences for myopathy were 0.0%, 0.1% and 0.3%. Similar dose-response relationships probably hold also for simvastatin. The longest clinical trial experience is available with lovastatin; in an ongoing study in 744 patients, the mean duration of therapy now exceeds 4 years in this study. 2.3% of patients have been discontinued because of drug-attributable adverse effects, mainly increased transaminases. No new adverse effects have appeared during prolonged use. Although cholesterol is the precursor of all steroid hormones, inhibitors of HMG-CoA reductase have been shown not to impair steroidogenesis. Unlike the fibrates, these drugs reduce biliary lithogenicity.
Dr Tobert concluded that simvastatin and lovastatin have been demonstrated to be well tolerated, safe and very effective in the treatment of hypercholesterolaemia.
Dr R L Jackson (USA) reported extensive data on the mechanism of action ofprobucol which apart from its lipid lowering effect, appears to have two other actions. It appears to act as an antoxidant and may prevent the oxidative modification of LDL that is required to produce foam cells in the genesis of the atherosclerotic fatty streak. The chemistry of its antoxidant properties has been well worked out and can be demonstrated both in vitro and in vivo in experiments with the Watanabe rabbit (an animal model of an LDL receptor deficiency). However there was no direct evidence from clinical studies that probucol exerts an antoxidant property and experiments such as seeing whether it reduces the antibodies to oxidized LDL in man should be undertaken.
Apart from its cholesterol lowering activities, probucol also lowers HDL but Dr Jackson said that this would be offset by an approximate 20-30% rise in cholesteryl-ester transfer protein which would possibly facilitate reverse cholesterol transport from the periphery back to the liver in the face oflow HDL levels.
The other major action of probucol is to reduce interleukin secretion which may be one of the major drives for smooth muscle cell proliferation. This may have an effect of reducing the cellularity of the atherosclerotic plaque and thereby prevent atherosclerosis without having any dramatic effects of blood lipid levels.
Dr R S Newton (USA) gave an account of the new developments in the fibric acid derivatives (particularly gemfibrozil) and the ACAT inhibitors in lowering LDL cholesterol and raising HDL cholesterol in animal models of dyslipidaemia and atherosclerosis. In order to examine the effects of the agents on the arterial wall, the cholesterol-fed rabbit model was used with endothelial injury to establish newly developing lesions. The animals were then randomized to either cholesteroVfat diets or diets with increasing dosages of the ACAT inhibitor or gemfibrozil. The high dose of the ACAT inhibitor showed a significant ability to reduce the cholesteryl ester content of the aortic wall lesions and morphometric evaluation showed reduced numbers of macrophage/foam .cells within the lesion. The effect of gemfibrozil was Journal of the Royal Society of Medicine Volume 83 November 1990 751 qualitatively significant. In the regression model (fed chow rather than high cholesterol high fat diets), no effects on the femoral lesion and foam cell numbers were noted in the drug treated groups.
In the same experimental system, nicotinic acid or combinations of nicotinic acid and cholestyramine, surprisingly had no effect on the progression of the arterial wall lesion. The percentage lesion coverage was 72% in the high cholesterol fed group and was reduced to 43% in the regression group, and to 31% with the ACAT inhibitors. Comparisons of actual and predicted foam cell numbers and lesion coverage of the aorta with the levels of plasma cholesterol indicated a strong relationship for drugs such as the ACAT inhibitors and the newer fibric acid derivatives such as gemfibrozil.
Dr G Ghiselli (Italy) then described new developments in the use of nicotinic acid derivatives such as acipimox for the inhibition offatty acid mobilization and reduction of triglyceride turnover in conditions when there is a high free fatty acid flux. The drug and its derivatives are believed to inhibit triglyceride lipolysis in adipose tissue and cause a rapid decrease in circulating fatty acids. This reduces hepatic triglyceride synthesis and thereby a reduction in plasma triglyceride levels. The reduction in plasma fatty acid flux also improves peripheral utilization of glucose, particularly in the non-insulin dependent diabetic patient. Acipimox has been used in clinical trials and has been shown to have an acute effect in lowering plasma fatty acid levels and thereafter reduction in plasma triglycerides. The mechanism of action and spectrum of activity mimics those of nicotinic acid but compared to the latter, the newer derivatives have an enhanced activity and a more prolonged action. It also has significantly fewer side effects related to vasomotor changes in the skin. The usefulness of the drug would primarily be in diabetics with hyperlipidaemia with the aim of delaying the onset of macrovascular disease which is found 3-4 times more commonly in the diabetic than non-diabetic matched subject.
Dr T Sanders (London) dealt with the role of polyunsaturated fatty acids in the treatment of hyperlipidaemias. There are two series of polyunsaturated fatty acids: the n-6 and n-S derived from linoleic and linolenic acid respectively. Linoleic acid is abundant in vegetable oils. Linolenic acid occurs in some vegetable oils such as linseed, soya and rapeseed oil. The long-chain derivatives of linolenic acid are found in fish oils, in particular eicosapentaenoic and docosahexaenoic acids.
A number of studies have evaluated the influence of these polyunsaturated fatty acids on lipoprotein metabolism in hyperlipidaemic patients. Studies have either given the polyunsaturated fatty acids in the form of a supplement or have exchanged a proportion of the habitual fat intake (usually saturated fat). Generally for each 1% energy of saturated fat replaced by either linoleic or linolenic acid there is a 0.12 mmol reduction in LDL cholesterol. With intakes above 12% of the energy, HDL cholesterol concentrations are reduced. There appears to be synergism between dietary modification and lipid lowering drugs.
The n-S polyunsaturated fatty acids have different effects on plasma lipids from linoleic acid and the effects observed are strongly dose related.
Both eicosapentaenoic acid (10:5n-3, EPA) and docosahexaenoic acid (22:6, DHA) can markedly lower plasma triglycerides and VLDL concentrations, linoleic acid and linolenic acid do not show the same effect at comparable doses. Moderate intakes of EPA and DHA increase HDL2 cholesterol but high intakes decrease HDL cholesterol.
As little as 1-2 g EPA and DHA (an amount equivalent to 100 g oily fish/day) can bring about a substantial reduction in plasma triglycerides in both normal and hypertriglyceridaemic patients. VLDL synthesis is decreased by moderate intakes and at high intakes (> 20 g n-3 fatty acids/day) LDL synthesis is also decreased. However, as with other triglyceride lowering agents such as fibrates, LDL levels tend to increase in patients with type IV and V hyperlipoproteinaemias. This may be a consequence of a reduction in VLDL particle size thus favouring the conversion of VLDL to LDL. EPA and DHA concentrates are not useful for the management of hypercholesterolaemia but are effective triglyceride lowering agents in patients with high levels ofVLDL and intermediate denisity lipoprotein. Animal studies show a synergistic LDL lowering effect of fish oil and the statins. High intakes of EPA and DHA may impair glucose homeostasis in non-insulin dependent diabetics and increase the requirement ofanti-oxidant nutrients in particular vitamin E. The latter may well be important in view ofthe knowledge the oxidative modification of low density lipoproteins is necessary for foam cell formation, an early event in the initiation of atherosclerosis.
The last speaker of the meeting was Professor James Shepherd (Glasgow) who addressed the
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Long-term parenteral nutrition: problems with venous access
It has long been recognized that parenteral nutrition can cause thrombosis in a relevant central vein, and Dr McIntyre (June 1990 JRSM, 371) correctly concludes that early referral to specialist centres is appropriate. Thrombosis may be a larger problem however than we realize.
The clinical diagnosis rate of 10-20% for thrombosis in association with central hyperalimentation may greatly underestimate its true incidence':". An incidence of 40-60%, found when routine contrast phlebography is used, makes thrombosis the most frequent complication of total parenteral nutrition (TPN). Wakefield" found that TPN solutions induce thrombogenicity by increasing the monocyte procoagulant activity both in vivo and in vitro.
problems of the economics of lipid lowering drug therapy. Although a number of intervention studies have established the clinical benefits of hypocholesterolaemic drug therapy, practical considerations dictate that these must be weighed against the costs of treatment, particularly since by consensus, up to 25% of the UK population may prove to be technically eligible for lipid lowering interventions.
In order to evaluate this problem, it is necessary to balance the costs of preventive therapy against the economic detractions associated with unchecked morbidity and mortality from heart disease. The latter has risen steadily by more than 10% per annum and currently exceeds £500 million to the NHS in England and Wales alone. Consideration of data accumulated by the Officeof Health Economics makes it clear that premature CHD deaths incur substantive additional economic burden to the community, in terms of lost productivity, increasing the economic attractiveness of supporting a CHD intervention and prevention programme.
Maximum benefit would accrue if the latter were targeted at young men with significantly elevated blood cholesterol levels who are exposed to additional coronary risk factors like diabetes mellitus, hypertension or cigarette smoking. The newly introduced potent HMG CoA reductase inhibitors make treatment of individuals with established coronary heart disease a particularly attractive proposition.
D J Galton Medical Unit, St Bartholomew's Hospital, West Smithfield, London Eel
Such enhanced monocyte procoagulant activity may be associated with intravascular thrombosis, and importantly in vitro at least, TPN solutions (20% dextrose, 10% amino acid solutions) may also induce endothelial cell procoagulant activity".
The procoagulant pathway is complex? but in essence is a T helper cell stimulated lymphokine mediated event where monocytes/macrophages are induced to synthesis and express on their cell surface, procoagulant activity. Inflammatory cytokines may then stimulate vascular endothelium similarly.
Two possible therapeutic modalities have been described. Firstly prostaglandin El and E2 have been successful in fulminant hepatitis in mice and men by blocking the monocyte/macrophage procoagulant activity8.9, and the concomitant use of lipid emulsion in the TPN regimen'", may also be helpful. 
